The receptor RAGE: Bridging inflammation and cancer
© Riehl et al; licensee BioMed Central Ltd. 2009
Received: 17 February 2009
Accepted: 08 May 2009
Published: 08 May 2009
The receptor for advanced glycation end products (RAGE) is a single transmembrane receptor of the immunoglobulin superfamily that is mainly expressed on immune cells, neurons, activated endothelial and vascular smooth muscle cells, bone forming cells, and a variety of cancer cells. RAGE is a multifunctional receptor that binds a broad repertoire of ligands and mediates responses to cell damage and stress conditions. It activates programs responsible for acute and chronic inflammation, and is implicated in a number of pathological diseases, including diabetic complications, stroke, atheriosclerosis, arthritis, and neurodegenerative disorders. The availability of Rage knockout mice has not only advanced our knowledge on signalling pathways within these pathophysiological conditions, but also on the functional importance of the receptor in processes of cancer. Here, we will summarize molecular mechanisms through which RAGE signalling contributes to the establishment of a pro-tumourigenic microenvironment. Moreover, we will review recent findings that provide genetic evidence for an important role of RAGE in bridging inflammation and cancer.
Both, RAGE and its downstream signalling pathways are key players in cellular response to stress conditions, such as inflammation . Induction of acute stress results in a transient synthesis and release of RAGE ligands, which induce an innate repair mechanism leading to a rapid but resolving response. However, in an environment of chronic stress with accumulation of ligands, RAGE triggers the conversion of acute cellular activation into sustained cellular response and tissue dysfunction [14, 17].
Regulation and function of RAGE in inflammation
Increased expression of RAGE has been documented in a variety of acute and chronic inflammatory diseases, such as septicaemia, rheumatoid arthritis, osteoarthritis, arteriosclerosis, chronic renal disease, inflammatory bowel disease, vasculitis and late diabetic complications (see references in ). In the past, numerous findings have advanced our knowledge on the molecular mechanisms through which RAGE could contribute to cellular processes of adaptive and innate immune responses [14, 15]. First, RAGE expression has been found on most key cell types linked integrally to an immune response, i.e. monocytes/macrophages, neutrophils, dendritic cells, as well as T and B lymphocytes [19–21] (Figure 1). Second, RAGE is expressed on endothelial cells and acts as an adhesion receptor for leukocytes by physical interaction with β2 integrin Mac-1. Interestingly, RAGE-Mac-1 interaction is induced by pro-inflammatory RAGE ligands in vitro and promotes leukocyte recruitment in mouse models of inflammation [22, 23]. Third, among the broad spectrum of extracellular ligands that trigger RAGE signalling, many have been functionally linked with acute and chronic immune responses [24–26]. Fourth, engagement of RAGE induces activation of the transcription factor NF-κB and some of its downstream target genes that are well-known regulators of the adaptive and innate immune system . It is worthwhile to note that RAGE also exhibits a functional NF-κB binding site in its proximal promoter and has been shown to be a direct target gene of NF-κB signalling . This might explain, at least in part, why RAGE expression is absent or very low in normal adult tissues, except for the lung, and increases under stress and pathological conditions [28–30]. Furthermore, ligands of RAGE have been shown to accumulate and trigger intracellular activation of NF-κB at sites of tissue damage and inflammation . This interconnected signalling enables a cycle of prolonged cellular response supporting the establishment of chronic tissue alterations . In addition, sustained NF-κB signalling in response to RAGE activation is also mediated by de novo RelA (p65) mRNA synthesis, which results in a growing pool of transcriptionally active NF-κB, overriding endogeneous negative feedback mechanisms .
Important insights regarding the specific function of RAGE in pathological conditions affected by innate and adaptive immune responses have been obtained from mouse models in which Rage signalling was inhibited. This was achieved by (i) administration of blocking antibodies or recombinant soluble RAGE (sRAGE), a truncated form that acts as a potent decoy-receptor for ligands, (ii) expression of a dominant-negative Rage (DN-Rage) transgene in genetically modified mice, and (iii) complete or tissue-specific deletion of Rage (Rage-/-). Treatment with sRAGE and expression of DN-Rage interfered with inflammatory conditions and revealed therapeutic effects in mouse models of diabetic atherosclerosis, delayed-type hypersensitivity (DTH), neuroinflammatory disorder, colitis, periodontitis, and others [18, 33]. However, it is important to note that sRAGE affects immune responses even in the absence of functional Rage, leading to the assumption that its beneficial effects in mouse disease models are not solely caused by preventing ligand engagement of Rage but also of other receptors . Studies with Rage-deficient mice provided further in vivo evidence for the central role of RAGE in initiation and perpetuation of immune responses . Although Rage-/- mice display a mild pro-inflammatory phenotype characterized by a moderately increased basal NF-κB activation and cytokine expression, they are protected from lethal septic shock in a model of cecal ligation and puncture (CLP), and survive in a Listeria monocytogenes infection model [34, 35].
While an important function of RAGE signalling is widely accepted in myeloid cells affecting primarily the innate immune response, opposing data were published in the context of the adaptive immune response. On the one hand, Liliensiek and colleagues reported that Rage-/- mice showed unchanged onset and progression of disease in models of DTH and experimental autoimmune encephalomyelitis (EAE), suggesting a normal T cell-dependent immune response . On the other hand, specific loss of Rage function in T lymphocytes impaired priming of adaptive immune responses in vivo [21, 36].
Regulation and function of RAGE in cancer
RAGE expression has been detected in a variety of human tumours, including brain, breast, colon, colorectal, lung, prostate, oral squamous cell, and ovarian cancer, as well as lymphoma and melanoma . Although our knowledge on the molecular function of RAGE during neoplastic transformation and malignant progression is limited, recent experimental data ranging from in vitro analyses to studies in mouse models and clinical data support a direct link between RAGE activation and proliferation, survival, migration, and invasion of tumour cells [37, 38]. Moreover, gene expression studies with samples of human patients and mouse tumour models revealed overexpression of RAGE ligands in most types of solid tumours [24, 39]. Taguchi and colleagues found that blockade of the Hmgb1-Rage axis suppressed tumour growth in two independent mouse models, and thereby provided for the first time experimental data for an in vivo function of Rage during cancer development . Yet, in contrast to the concept of RAGE as a potent inducer of tumour growth and malignant conversion, few reports raised the perception that it also has tumour-suppressive functions in distinct cell types. As an example, RAGE is highly expressed in lung tissue, especially at the site of alveolar epithelium, and its expression is significantly reduced in lung carcinomas [41, 42]. This suggests that lung cancer progression may be enhanced by loss of RAGE function and indeed re-expression of RAGE in lung tumour cell lines reduced their proliferation and revealed diminished tumour growth in athymic mice [43–45]. In addition, functional inactivation of RAGE in myoblasts resulted in reduced myogenesis and enhanced proliferation and invasion in vitro as well as increased tumour growth in vivo [46, 47]. Nevertheless, tissue-specific differences in levels of RAGE expression, its splice variants, and ligands give room for the speculation that RAGE might exhibit tumour-suppressive functions in tissues characterized by constitutive RAGE expression, while it fulfils a tumour-promoting role in tissues with inducible RAGE expression.
RAGE in inflammation-associated cancer
Given the evidence from a large body of experimental data that signals downstream of RAGE can fuel chronic inflammatory conditions (see above), one could speculate on its potential impact on creating a microenvironment that is ideal for neoplastic transformation and malignant conversion (Figure 1). Indeed, the usage of Rage-deficient mice (Rage-/-) in well-established mouse models of inflammation-associated carcinogenesis, such as chemically induced skin carcinogenesis and colitis-associated cancer, provided direct genetic evidence for a novel role of Rage signalling in linking chronic inflammation and cancer [20, 48]. Chemically induced skin carcinogenesis is one of the best-established in vivo models to study the multistage nature of tumour development. Moreover, it represents a classical inflammation-associated tumour model, as its promotion phase solely depends on repeated topical treatments with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a potent inducer of dermal inflammation . We could show that Rage-/- mice were almost resistant to 9,10-dimethyl-1,2-benzanthracene (DMBA)/TPA-induced skin carcinogenesis and that the few tumours that developed in the absence of Rage were smaller in size, less progressed, highly differentiated, and hyperkeratotic . Importantly, dramatically decreased levels of pro-inflammatory mediators (e.g. Ptgs2, S100a8, S100a9, and macrophage inflammatory proteins) and reduced numbers of infiltrating immune cells accompanied impaired tumour formation in Rage-/- animals. These data suggest a severe defect in sustaining inflammatory conditions during the promotion phase. One intriguing finding of the study was the ability of Rage to induce its own ligands, as we found strongly induced S100a8 and S100a9 expression in epithelial cells only in the presence of Rage. Hence, the S100-Rage axis might generate a feed-forward loop that further aggravates an inflammatory environment . In addition, S100A8/S100A9 could directly induce proliferation of tumour cells via RAGE ligation, as was shown recently in a cell culture model . Bearing in mind the importance of the pro-inflammatory microenvironment in tumour development, it is interesting to note, that bone marrow chimera experiments revealed Rage expression on immune cells, but not keratinocytes or endothelial cells, to be essential for innate immune cell recruitment and induction of epidermal hyperplasia in vivo . This is in line with published data on a model of HMGB1-induced peritonitis . Nevertheless, Rage expression on keratinocytes might also contribute to the transformation and malignant progression of epithelial cells, and it will be a challenge for the future to investigate cell type-specific Rage knockout mice using the DMBA/TPA tumour model.
In line with the data obtained from the model of inflammation-associated skin carcinogenesis, Turovskaya and colleagues demonstrated a crucial role for Rage in a mouse model of colitis-induced cancer (CAC) . Although Rage was dispensable for initial acute inflammation, Rage-/- mice showed defects in the transition to chronic inflammatory conditions and revealed significantly less tumours. Interestingly, impaired CAC was not only observed in Rage-/- mice, but also in wt mice after administration of mAbGB3.1, a monoclonal anti-carboxylate glycan antibody . Glycosylation of the extracellular part of RAGE significantly increases receptor affinity for HMGB1 and S100 proteins. In addition, carboxylated glycans were found on a subset of RAGE on colon cancer cells [51, 52].
A common feature of both mouse models, chemically induced skin carcinogenesis and CAC, was a reduced number of Gr1+CD11b+ myeloid precursor cells in the absence of Rage function, implying that RAGE signalling also contributes to the development and recruitment of myeloid-derived suppressor cells (MDSCs). Accumulation of MDSCs is one of the major immunological abnormalities in cancer resulting in T cell tolerance and suppression of anti-tumour immune response  (Figure 1). The molecular mechanisms of this phenomenon remain largely undefined, however, a recent study demonstrated that tumour-induced and Stat3-dependent up-regulation of S100a8 and S100a9 proteins in myeloid precursor cells are necessary for the accumulation of Gr1+CD11b+MDSCs . Moreover, Sinha and colleagues found that S100a8/S100a9 produced and secreted by tumour cells binds to Rage on MDSCs and promotes their migration and accumulation through NF-κB signalling pathways .
Conclusion and perspective
In summary, the published data propose that RAGE signalling drives the strength and maintenance of an inflammatory response and serves as a key player in bridging chronic inflammation and cancer. Accordingly, compelling data from diverse animal models have provided a rationale for targeting RAGE as a novel strategy for clinical interventions, and thereby, hit two important compartments during carcinogenesis: the transformed tumour cells as well as the pro-tumourigenic microenvironment. Several approaches have been considered to pharmacologically antagonize RAGE or RAGE ligand-induced pathologies, including cancer [18, 35]. Despite these promising results, the tumour-suppressive functions of RAGE that were observed in specific tissues raise concerns against the therapeutic use of RAGE inhibitors and hamper a systemic application of such. Furthermore, no long-term studies using sRAGE, blocking antibodies, or small molecule inhibitors are available yet, necessary to appraise potential side effects. This is of particular interest, as RAGE has been shown to be important for cellular repair and tissue regeneration/homeostasis .
Altogether, there is an urgent need for a better and comprehensive understanding of the molecular mechanisms through which RAGE executes its beneficial function during acute responses and tissue homeostasis or contributes to a feed-forward signalling in severe chronic disorders, including cancer. Despite the fact that RAGE has been identified almost two decades ago, it still retains a lot of its mystery (Figure 2). Therefore, systemic and genome-wide approaches will be required to solve the complexity of RAGE-dependent signalling pathways and gene regulatory networks, also with respect to the functional crosstalk with other receptors such as Toll-like receptors . Eventually, the availability of a large variety of informative mouse models and some distinct downstream target genes will be a promising starting point for novel drug development and drug assessment in the near future.
We gratefully acknowledge Heike Peterziel for helpful discussion and critical reading of the manuscript. Our work was supported by the German Ministry for Education and Research (National Genome Research Network NGFN-2 to P.A.), the Cooperation in Cancer Research of the Deutsche Krebforschungszentrum and Israeli's Ministry of Science, Culture and Sport (to P.A. and J.H.), and the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Systems Biology (to P.A. and J.H.).
- Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002, 420: 860-867. 10.1038/nature01322.PubMed CentralView ArticlePubMedGoogle Scholar
- Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357: 539-545. 10.1016/S0140-6736(00)04046-0.View ArticlePubMedGoogle Scholar
- de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6: 24-37. 10.1038/nrc1782.View ArticlePubMedGoogle Scholar
- Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444. 10.1038/nature07205.View ArticlePubMedGoogle Scholar
- Germano G, Allavena P, Mantovani A: Cytokines as a key component of cancer-related inflammation. Cytokine. 2008, 43: 374-379. 10.1016/j.cyto.2008.07.014.View ArticlePubMedGoogle Scholar
- Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007, 117: 1175-1183. 10.1172/JCI31537.PubMed CentralView ArticlePubMedGoogle Scholar
- Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759. 10.1038/nri1703.View ArticlePubMedGoogle Scholar
- Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008, 18: 3-10. 10.1016/j.gde.2008.01.003.View ArticlePubMedGoogle Scholar
- Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001, 108: 949-955.PubMed CentralView ArticlePubMedGoogle Scholar
- Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005, 83: 876-886. 10.1007/s00109-005-0688-7.View ArticlePubMedGoogle Scholar
- Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T: The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Letters. 2003, 550: 107-113. 10.1016/S0014-5793(03)00846-9.View ArticlePubMedGoogle Scholar
- Hudson BI, Kalea AZ, Arriero MD, Harja E, Boulanger E, D'Agati V, Schmidt AM: Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008, 283: 34457-34468. 10.1074/jbc.M801465200.PubMed CentralView ArticlePubMedGoogle Scholar
- Donato R: RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins. Curr Mol Med. 2007, 7: 711-724. 10.2174/156652407783220688.View ArticlePubMedGoogle Scholar
- Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM: Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med. 2007, 7: 743-751. 10.2174/156652407783220714.View ArticlePubMedGoogle Scholar
- Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM: Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol. 2007, 82: 204-212. 10.1189/jlb.1206751.View ArticlePubMedGoogle Scholar
- Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth P, Martin E, Weigand M: Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care. 2008, 12: 201-10.1186/cc6164.PubMed CentralView ArticlePubMedGoogle Scholar
- Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP: Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci. 2005, 1043: 676-680. 10.1196/annals.1333.077.View ArticlePubMedGoogle Scholar
- Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic target?. Curr Opin Investig Drugs. 2006, 7: 985-991.PubMedGoogle Scholar
- Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, Schmidt AM, Stern DM, Al-Mohanna FA: RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol. 2002, 71: 433-444.PubMedGoogle Scholar
- Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P: RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. 2008, 205: 275-285. 10.1084/jem.20070679.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC: RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008, 181: 4272-4278.PubMed CentralView ArticlePubMedGoogle Scholar
- Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003, 198: 1507-1515. 10.1084/jem.20030800.PubMed CentralView ArticlePubMedGoogle Scholar
- Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. Embo J. 2007, 26: 1129-1139. 10.1038/sj.emboj.7601552.PubMed CentralView ArticlePubMedGoogle Scholar
- Gebhardt C, Nemeth J, Angel P, Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006, 72: 1622-1631. 10.1016/j.bcp.2006.05.017.View ArticlePubMedGoogle Scholar
- Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007, 81: 28-37. 10.1189/jlb.0306170.View ArticlePubMedGoogle Scholar
- Bianchi ME, Manfredi AA: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007, 220: 35-46. 10.1111/j.1600-065X.2007.00574.x.View ArticlePubMedGoogle Scholar
- Li J, Schmidt AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 1997, 272: 16498-16506. 10.1074/jbc.272.26.16498.View ArticlePubMedGoogle Scholar
- Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, et al.: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993, 143: 1699-1712.PubMed CentralPubMedGoogle Scholar
- Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP: Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 2006, 323: 475-488. 10.1007/s00441-005-0069-0.View ArticlePubMedGoogle Scholar
- Tanaka TS, Jaradat SA, Lim MK, Kargul GJ, Wang X, Grahovac MJ, Pantano S, Sano Y, Piao Y, Nagaraja R, Doi H, Wood WH, Becker KG, Ko MS: Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. Proc Natl Acad Sci USA. 2000, 97: 9127-9132. 10.1073/pnas.97.16.9127.PubMed CentralView ArticlePubMedGoogle Scholar
- Schmidt AM, Yan SD, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000, 1498: 99-111. 10.1016/S0167-4889(00)00087-2.View ArticlePubMedGoogle Scholar
- Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001, 50: 2792-2808. 10.2337/diabetes.50.12.2792.View ArticlePubMedGoogle Scholar
- Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM: RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci. 2002, 59: 1117-1128. 10.1007/s00018-002-8491-x.View ArticlePubMedGoogle Scholar
- Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hämmerling GG, Nawroth PP, Arnold B: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004, 113: 1641-1650.PubMed CentralView ArticlePubMedGoogle Scholar
- Lutterloh EC, Opal SM, Pittman DD, Keith JC, Tan XY, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, Parejo NA, Kessimian N: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007, 11: R122-10.1186/cc6184.PubMed CentralView ArticlePubMedGoogle Scholar
- Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, Schmidt AM, Brown C, Stern A, LaFaille J, Chess L, Stern DM, Jiang H: Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med. 2003, 9: 287-293. 10.1038/nm831.View ArticlePubMedGoogle Scholar
- Logsdon CD, Fuentes MK, Huang EH, Arumugam T: RAGE and RAGE ligands in cancer. Curr Mol Med. 2007, 7: 777-789. 10.2174/156652407783220697.View ArticlePubMedGoogle Scholar
- Abe R, Yamagishi S: AGE-RAGE system and carcinogenesis. Curr Pharm Des. 2008, 14: 940-945. 10.2174/138161208784139765.View ArticlePubMedGoogle Scholar
- Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007, 13: 2836-2848. 10.1158/1078-0432.CCR-06-1953.View ArticlePubMedGoogle Scholar
- Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000, 405: 354-360. 10.1038/35012626.View ArticlePubMedGoogle Scholar
- Schraml P, Bendik I, Ludwig CU: Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res. 1997, 57: 3669-3671.PubMedGoogle Scholar
- Stav D, Bar I, Sandbank J: Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma. Int J Biol Markers. 2007, 22: 108-113.PubMedGoogle Scholar
- Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis. 2005, 26: 293-301. 10.1093/carcin/bgh333.View ArticlePubMedGoogle Scholar
- Bartling B, Demling N, Silber RE, Simm A: Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol. 2006, 34: 83-91. 10.1165/rcmb.2005-0194OC.View ArticlePubMedGoogle Scholar
- Kobayashi S, Kubo H, Suzuki T, Ishizawa K, Yamada M, He M, Yamamoto Y, Yamamoto H, Sasano H, Sasaki H, Suzuki S: Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. Am J Respir Crit Care Med. 2007, 175: 184-189. 10.1164/rccm.200602-212OC.View ArticlePubMedGoogle Scholar
- Riuzzi F, Sorci G, Donato R: The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem. 2006, 281: 8242-8253. 10.1074/jbc.M509436200.View ArticlePubMedGoogle Scholar
- Riuzzi F, Sorci G, Donato R: RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol. 2007, 171: 947-961. 10.2353/ajpath.2007.070049.PubMed CentralView ArticlePubMedGoogle Scholar
- Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G: RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008, 29: 2035-2043. 10.1093/carcin/bgn188.PubMed CentralView ArticlePubMedGoogle Scholar
- Furstenberger G, Kopp-Schneider A: Malignant progression of papillomas induced by the initiation – promotion protocol in NMRI mouse skin. Carcinogenesis. 1995, 16: 61-69. 10.1093/carcin/16.1.61.View ArticlePubMedGoogle Scholar
- Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C, Los M: S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008, 83: 1484-1492. 10.1189/jlb.0607397.PubMed CentralView ArticlePubMedGoogle Scholar
- Srikrishna G, Huttunen HJ, Johansson L, Weigle B, Yamaguchi Y, Rauvala H, Freeze HH: N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem. 2002, 80: 998-1008. 10.1046/j.0022-3042.2002.00796.x.View ArticlePubMedGoogle Scholar
- Srikrishna G, Turovskaya O, Shaikh R, Newlin R, Foell D, Murch S, Kronenberg M, Freeze HH: Carboxylated glycans mediate colitis through activation of NF-kappa B. J Immunol. 2005, 175: 5412-5422.View ArticlePubMedGoogle Scholar
- Marx J: Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science. 2008, 319: 154-156. 10.1126/science.319.5860.154.View ArticlePubMedGoogle Scholar
- Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI: Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008, 205: 2235-2249. 10.1084/jem.20080132.PubMed CentralView ArticlePubMedGoogle Scholar
- Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G: Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008, 181: 4666-4675.PubMed CentralView ArticlePubMedGoogle Scholar
- Lin L: RAGE on the Toll Road?. Cell Mol Immunol. 2006, 3: 351-358.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.